JNJeannette Navarrete

Jeannette Navarrete

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeannette Navarrete has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identificación de polimorfismos en el gen mieloperoxidasa y su papel en candidiasis vulvovaginal recurrente por Candida spp., aisladas de pacientes de Bogotá DC

    by María Paula Montoya, Gloria Julieth Rincón, Julián Esteban Muñoz, Sharon Hassbleidy Ochoa, Claudia Andrea Cruz, Jeanette Navarrete

    Introduction: Myeloperoxidase (MPO) is an antimicrobial protein present in the azuro- philic granules of neutrophils, its action falls when it is conjugated in the phagosome with hydrogen peroxide, resulting in toxic substances for phagocytosed microorganisms. Seve- ral authors have described that recurrent vulvovaginal infections by Candida spp., are rela- ted to primary MPO deficiency, which is an autosomal recessive disorder, due to polymor- phisms associated with posttranslational processing or pre-translational errors. Objective: To identify the relationship between the two MPO polymorphisms (Y173C-M251T) with a higher probability of presenting vulvovaginal infection. Materials and methods: 27 blood samples were collected from women between 20-45 years old diagnosed with vul- vovaginal candidiasis in order to analyze the complete blood count, Wright stain, leuko- cyte peroxidase stain and perform DNA extraction to assess the quantity and quality of genetic material. Subsequently, primers for the mpo gene were designed by bioinformatic tools and the conditions to standardize conventional PCR were established. Amplified products were sequenced by capillary electrophoresis (CES) to identify polymorphisms. Results: The polymorphisms of interest were not found in any sample. However, nucleoti- de changes were found in exons 4 and 6 of the fragment studied in two samples analyzed, indicating that this region may present genetic variability. Conclusion: The present study is a first approximation in Colombia on the mpo gene polymorphisms from patients with vulvovaginal Candidiasis in Bogotá D.C. Future studies with a more representative num- ber of samples will give us stronger indications of the genetic variability that the mpo gene may present.

  • Open Access

    Congenital syphilis confirmed by PCR as a result of treatment failure for syphilis in pregnancy. Case report

    by Mery Yolanda Cifuentes Cifuentes, Linda Stefany Gómez Aristizábal, Gladys Pinilla Bermúdez, Claudia Cruz, Jeannette Navarrete

    Introduction: Congenital syphilis is a major public health problem, and early diagnosis and treatment are necessary to prevent it. Penicillin G benzathine is the treatment of choice in pregnant women; however, it may fail to prevent fetal infection, as in the present case. Case presentation: Male newborn, son of an HIV negative mother with gestational syphilis (venereal disease research laboratory (VDRL) 1:4 dilution, positive treponemal test) diagnosed at week 21 of gestation and treated with three doses of 2 400 000 IU of penicillin G benzathine. At delivery, the mother presented VDRL 1:1 dilution. The newborn was diagnosed with congenital syphilis due to VDRL 1:4 dilution, positive treponemal test, elevated aspartate aminotransferases, hyposthenuria, proteinuria, hematuria, and leukocyturia that resolved after treatment with crystalline penicillin for 10 days. The molecular testing in blood showed a high treponemal load. The VDRL test at 3 months was non-reactive. Conclusions: Preventing congenital syphilis with the recommended treatment for gestational syphilis may fail. Moreover, diagnosing this condition in an asymptomatic newborn is difficult. Therefore, clinical and serological tests are recommended to confirm whether maternal treatment was effective in the fetus.


  • Open Access

    Peptides DLL37-1 and LL37-1, an alternative to inhibit biofilm formation in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis

    by Maryi Lorena Segura Alba, Andrea Tatiana Durán-Rodriguez, Luz Mary Salazar Pulido, Javier Escobar-Pérez, Sergio Alejandro Gutiérrez, Jeannette Navarrete Ospina, Gladys Pinilla Bermúdez, Liliana Constanza Muñoz Molina

    Staphylococcus aureus and Staphylococcus epidermidis have microbial surface components recognizing adhesive matrix molecules (MSCRAMM) adhesion proteins that enhance their biofilm formation ability, as well as virulence factors that influence morbidity and mortality in hospital settings. In this work, four peptides analogous of the peptide LL-37 that were evaluated to inhibit biofilm formation and its action potential on the expression of MSCRAMM proteins in clinical isolates through different tests, such as crystal violet, PCR and qPCR. In total, 96.8% of S. aureus were strong in biofilm formation in contrast to 48.4% of S. epidermidis. sdrG and sdrF genes were present in 100% of S. epidermidis strains and in all isolates. In S. aureus, specific genes that code for MSCRAMM proteins were detected: clfA (89%), clFB, sdrC and fnBA (94%). The peptides did not show hemolytic or cytotoxic activity. In this study, it was evidenced that of the peptides DLL37-1 at a 5 µM concentration was an efficacious antimicrobial agent and depicted greater biofilm inhibition in both bacterial species. Exhibiting a significant inhibition rate in S. aureus, this peptide caused a negative regulation in the expression of the genes clfA and sdrC, showed greater biological activity.